Drug Delivery System Comprising a Tetrahydroxilated Estrogen for Use in Hormonal Contraception
US 7,732,430 In forceTerm ends Jan 15, 2028 · High confidence
20-year base term ended May 23, 2022
May 23, 2002
Jan 15, 2028
Jun 8, 2010
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 23, 2002, when the earliest non-provisional application in its chain was filed (this one was filed May 25, 2004) | May 23, 2022 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +1014 days, USPTO patent term adjustment record | Mar 2, 2025 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | +1,049 days, USPTO 35 U.S.C. 156 certificate | added to Mar 2, 2025: Jan 15, 2028 | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 15, 2028 | High confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.